L3VLUP
ProSign in

REGN · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

REGNLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • REGN
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterREGNLLY
Q3 202024 holders, $17.4bn33 holders, $14.1bn
Q4 202026 holders, $15.2bn29 holders, $17.3bn
Q1 202122 holders, $13.7bn24 holders, $23.0bn
Q2 202127 holders, $15.3bn24 holders, $27.8bn
Q3 202126 holders, $15.5bn31 holders, $29.9bn
Q4 202128 holders, $16.3bn31 holders, $34.7bn
Q1 202225 holders, $19.2bn24 holders, $35.3bn
Q2 202226 holders, $16.5bn33 holders, $42.7bn
Q3 202224 holders, $19.0bn31 holders, $43.4bn
Q4 202230 holders, $20.2bn31 holders, $46.6bn
Q1 202332 holders, $22.3bn33 holders, $44.3bn
Q2 202328 holders, $18.8bn37 holders, $59.6bn
Q3 202326 holders, $21.1bn44 holders, $67.6bn
Q4 202335 holders, $21.9bn45 holders, $73.6bn
Q1 202428 holders, $23.6bn41 holders, $95.3bn
Q2 202428 holders, $25.6bn43 holders, $110bn
Q3 202431 holders, $25.0bn45 holders, $107bn
Q4 202427 holders, $13.8bn46 holders, $93.9bn
Q1 202529 holders, $12.2bn42 holders, $98.4bn
Q2 202532 holders, $9.3bn43 holders, $93.2bn
Q3 202533 holders, $10.1bn39 holders, $86.7bn
Q4 202533 holders, $16.3bn41 holders, $123bn
Q1 202624 holders, $15.2bn39 holders, $106bn
Q2 202622 holders, $10.6bn44 holders, $132bn
REGN

Regeneron Pharmaceuticals

Holders
27
Reported value
$13.8bn
Buyers
17
Sellers
12

Breadth +5 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
46
Reported value
$93.9bn
Buyers
24
Sellers
23

Breadth +1 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2024

Among the 50 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only REGN (4)

ARK Investment Management LLC, Caxton Associates LLP, PDT Partners LLC, Tudor Investment Corp

Only LLY (23)

Artisan Partners LP, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Citadel Advisors LLC, Coatue Management LLC, Egerton Capital UK LLP, Freestone Grove Partners LP, GAMCO Investors Inc, Holocene Advisors LP, Jane Street Group LLC, Janus Henderson Group Ltd, Lone Pine Capital LLC, MFS Investment Management, Polen Capital Management LLC, Quantbot Technologies LP, Rokos Capital Management LLP, Soros Fund Management LLC, Susquehanna International Group LLP, Tiger Global Management LLC, Two Sigma Advisers LP, Wellington Management Group LLP, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →